When the FDA approved Foundayo earlier this month, it marked a quiet milestone for the 70 percent of American adults with obesity: for the first time, people could access a new class of weight loss medication as a simple pill instead of a weekly injection.
The drug, developed by Eli Lilly and containing the active ingredient orforglipron, passed through a new FDA pilot program designed to accelerate reviews when preliminary evidence suggests a medicine's benefits clearly outweigh its risks. It is now the second oral GLP-1 drug available in the United States, joining the oral version of Wegovy, which contains the older compound semaglutide.
The approval came with strings attached—and that detail, experts say, reflects something worth celebrating about how the system works.
The FDA has asked Eli Lilly to conduct additional studies tracking potential risks including heart attack, stroke, drug-related liver injury, and delayed stomach emptying. The agency also wants the company to monitor patients for at least 15 years for any possible link to thyroid cancer. Separate registries will track children with obesity who use the drug and outcomes in pregnant patients.
"It doesn't mean a safety problem has been found," Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in Cary, North Carolina, told NBC News. "It means they want more definitive long-term data."
The distinction matters. Orforglipron is a newer, non-peptide formulation of GLP-1—a hormone that regulates appetite and blood sugar. Unlike semaglutide, which has been studied since 2017, orforglipron lacks the same depth of long-term safety records. The FDA did not request similar post-approval studies when the oral version of Wegovy was approved, precisely because its compound is far more established.
An Eli Lilly spokesperson emphasized that such requirements are routine for newer compounds. "Patient safety is Lilly's top priority and we actively monitor, evaluate and report safety information for all our medicines," the spokesperson said.
For millions of people who have struggled with injectable medications—some due to needle aversion, others due to cost or access barriers—Foundayo represents a meaningful new option. The pill format may expand who feels able to pursue medical treatment for obesity at all.
The 15-year thyroid monitoring requirement is notable, but injectable GLP-1 drugs already carry a boxed warning about this potential risk. The new research will ultimately deepen understanding of the entire drug class, benefiting patients far beyond those who take Foundayo.
In other words, the FDA isn't pumping the brakes. It's keeping the road well-lit.